Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $485 from $425 and keeps an Underweight rating on the shares following the earnings report. The firm says it was “overly bearish” on Medpace’s demand environment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace Holdings Reports Strong Q3 2025 Results
- Medpace Holdings Inc. Reports Strong Q3 2025 Growth
- Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning
- Closing Bell Movers: Tesla and IBM fall as Q3 results disappoint
- Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns